INTERFERON BETA-1A for Clinically isolated syndrome: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 14 adverse event reports in the FDA FAERS database where INTERFERON BETA-1A was used for Clinically isolated syndrome.
Most Reported Side Effects for INTERFERON BETA-1A
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Multiple sclerosis relapse | 5,931 | 8.8% | 45 | 3,123 |
| Influenza like illness | 4,475 | 6.6% | 12 | 861 |
| Memory impairment | 3,468 | 5.1% | 3 | 547 |
| Multiple sclerosis | 3,412 | 5.1% | 185 | 960 |
| Fatigue | 3,164 | 4.7% | 11 | 736 |
| Fall | 3,128 | 4.6% | 48 | 1,571 |
| Gait disturbance | 3,031 | 4.5% | 18 | 892 |
| Death | 2,766 | 4.1% | 2,765 | 127 |
| Pain | 2,692 | 4.0% | 19 | 677 |
| Headache | 2,533 | 3.8% | 8 | 667 |
| Drug ineffective | 2,238 | 3.3% | 19 | 449 |
| Injection site pain | 2,132 | 3.2% | 2 | 356 |
| Malaise | 2,000 | 3.0% | 24 | 510 |
| Pyrexia | 1,688 | 2.5% | 21 | 574 |
| Hypoaesthesia | 1,685 | 2.5% | 5 | 490 |
Other Indications for INTERFERON BETA-1A
Multiple sclerosis (56,475)
Product used for unknown indication (7,473)
Relapsing-remitting multiple sclerosis (2,058)
Maternal exposure timing unspecified (245)
Relapsing multiple sclerosis (192)
Secondary progressive multiple sclerosis (89)
Covid-19 (31)
Primary progressive multiple sclerosis (27)
Exposure via father (20)
Progressive multiple sclerosis (19)
Other Drugs Used for Clinically isolated syndrome
OFATUMUMAB (1,075)
SIPONIMOD (147)
GLATIRAMER (59)
FINGOLIMOD (18)
INTERFERON BETA-1B (18)
OZANIMOD (18)
DIMETHYL (7)